메뉴 건너뛰기
Transplantation
Volumn 100, Issue 7, 2016, Pages 1390-1392
Belatacept: A game changer?
Author keywords

[No Author keywords available]
Indexed keywords

BELATACEPT; CYCLOSPORIN; TACROLIMUS; ABATACEPT;
EID: 84976274909     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0000000000001268     Document Type: Short Survey
Times cited : (7)
References (10)
  • 1
    • 84955444904 scopus 로고    scopus 로고
    • Belatacept and long-termoutcomes in kidney transplantation
    • Vincenti F, Rostaing L, Grinyo J, et al. Belatacept and long-termoutcomes in kidney transplantation. N Engl JMed. 2016;374:333-343.
    • (2016) N Engl JMed. , vol.374 , pp. 333-343
    • Vincenti, F.1    Rostaing, L.2    Grinyo, J.3
  • 2
    • 76949101581 scopus 로고    scopus 로고
    • A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study)
    • Vincenti F, Charpentier B, Vanrenterghem Y, et al. A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study). Am J Transplant. 2010;10:535-546.
    • (2010) Am J Transplant. , vol.10 , pp. 535-546
    • Vincenti, F.1    Charpentier, B.2    Vanrenterghem, Y.3
  • 3
    • 78650831358 scopus 로고    scopus 로고
    • Belatacept-based regimens versus a cyclosporine A-based regimen in kidney transplant recipients: 2-year results from the BENEFIT and BENEFIT-EXT studies
    • Larsen CP, Grinyó J, Medina-Pestana J, et al. Belatacept-based regimens versus a cyclosporine A-based regimen in kidney transplant recipients: 2-year results from the BENEFIT and BENEFIT-EXT studies. Transplantation. 2010;90:1528-1535.
    • (2010) Transplantation. , vol.90 , pp. 1528-1535
    • Larsen, C.P.1    Grinyó, J.2    Medina-Pestana, J.3
  • 4
    • 84855939763 scopus 로고    scopus 로고
    • Three-year outcomes from BENEFIT, a randomized, active-controlled, parallel-group study in adult kidney transplant recipients
    • Vincenti F, Larsen CP, Alberu J, et al. Three-year outcomes from BENEFIT, a randomized, active-controlled, parallel-group study in adult kidney transplant recipients. Am J Transplant. 2012;12:210-217.
    • (2012) Am J Transplant. , vol.12 , pp. 210-217
    • Vincenti, F.1    Larsen, C.P.2    Alberu, J.3
  • 5
    • 84886791910 scopus 로고    scopus 로고
    • Long-term belatacept exposure maintains efficacy and safety at 5 years: Results from the long-term extension of the BENEFIT study
    • Rostaing L, Vincenti F, Grinyó J, et al. Long-term belatacept exposure maintains efficacy and safety at 5 years: results from the long-term extension of the BENEFIT study. Am J Transplant. 2013;13:2875-2583.
    • (2013) Am J Transplant. , vol.13 , pp. 2583-2875
    • Rostaing, L.1    Vincenti, F.2    Grinyó, J.3
  • 6
    • 84931073842 scopus 로고    scopus 로고
    • Does belatacept improve outcomes for kidney transplant recipients A systematic review
    • Talawila N, Pengel LH. Does belatacept improve outcomes for kidney transplant recipients A systematic review. Transpl Int. 2015;28:1251-1264.
    • (2015) Transpl Int. , vol.28 , pp. 1251-1264
    • Talawila, N.1    Pengel, L.H.2
  • 7
    • 84896366459 scopus 로고    scopus 로고
    • Projecting long-term graft and patient survival after transplantation
    • Levy AR, Briggs AH, Johnston K, et al. Projecting long-term graft and patient survival after transplantation. Value Health. 2014;17:254-260.
    • (2014) Value Health. , vol.17 , pp. 254-260
    • Levy, A.R.1    Briggs, A.H.2    Johnston, K.3
  • 8
    • 84961937790 scopus 로고    scopus 로고
    • Indirect treatment comparison of belatacept versus tacrolimus from a systematic review of immunosuppressive therapies for kidney transplant patients
    • [Epub ahead of print]
    • Muduma G, Hart WM, Patel S, et al. Indirect treatment comparison of belatacept versus tacrolimus from a systematic review of immunosuppressive therapies for kidney transplant patients. Curr Med Res Opin. 2016:1-30. [Epub ahead of print].
    • (2016) Curr Med Res Opin. , pp. 1-30
    • Muduma, G.1    Hart, W.M.2    Patel, S.3
  • 9
    • 84976260383 scopus 로고    scopus 로고
    • An acute cellular rejection with detrimental outcome occurring under belatacept-based immunosuppressive therapy: An immunological analysis
    • [Epub ahead of print]
    • de Graav GN, Hesselink DA, Dieterich M, et al. An acute cellular rejection with detrimental outcome occurring under belatacept-based immunosuppressive therapy: An immunological analysis. Transplantation, [Epub ahead of print].
    • Transplantation
    • De Graav, G.N.1    Hesselink, D.A.2    Dieterich, M.3
  • 10
    • 84954338806 scopus 로고    scopus 로고
    • CD57+ CD4 Tcells underlie belataceptresistant allograft rejection
    • Espinosa J, Herr F, Tharp G, et al. CD57+ CD4 Tcells underlie belataceptresistant allograft rejection. Am J Transplant. 2016;16:1102-1112.
    • (2016) Am J Transplant. , vol.16 , pp. 1102-1112
    • Espinosa, J.1    Herr, F.2    Tharp, G.3

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.